Niagen Bioscience (NASDAQ: NAGE) has expanded the retail footprint of its flagship product, Tru Niagen, by securing placement in nearly 300 GNC and Sam’s Club locations across 44 states in the United States. The company stated that this distribution growth places its category-leading NAD+ supplement in front of new consumer audiences, reflecting growing demand for science-backed healthy aging solutions.

Retail Distribution Details

The company differentiated its product offerings between the two retail partners to address specific consumer needs:

• GNC: Shoppers can purchase Tru Niagen Beauty, described as the first beauty supplement in the US featuring Niagen (patented nicotinamide riboside or NR). This variant supports skin elasticity and the appearance of hair, skin, and nails. GNC also stocks Tru Niagen 300mg 30-count bottles.
• Sam’s Club: The retailer offers Tru Niagen 300mg 120-count bottles.

Both retailers make these products available in-store and online via www.gnc.com and www.samsclub.com .

Product Science and Market Position

Tru Niagen is powered by Niagen, which the company identifies as the most well-researched and efficient NAD-booster available. The product is clinically shown to increase NAD+ levels, an essential coenzyme for cellular health, mitochondrial function, and DNA repair.

Niagen Bioscience cited the following scientific backing for its portfolio:

• More than 45 human clinical studies.
• Over 500 published scientific studies.
• More than 60 patents worldwide.

The company noted that Tru Niagen is currently the number one healthy-aging NAD-boosting supplement in the United States based on revenue per the largest US e-commerce marketplace from January 2025 to December 2025.

Strategic Outlook

Rob Fried, CEO of Niagen Bioscience, said the partnerships with GNC and Sam’s Club strengthen the company’s retail presence. He emphasized that the expansion reflects credible demand for healthy aging solutions backed by rigorous scientific standards.

The company continues to focus on advancing healthspan through precision science, with its portfolio including consumer supplements and pharmaceutical-grade Niagen products available exclusively at clinics with a prescription.

Niagen Bioscience, Inc. (NASDAQ: NAGE) has selected Evotec (NASDAQ: EVO) to lead preclinical development activities for NB4168, a proprietary oral small-molecule candidate targeting Ataxia Telangiectasia (A-T). The collaboration aims to generate the pharmacological evidence required to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking a critical step toward initiating human clinical trials for a rare pediatric disease with no approved therapies.

The agreement designates Evotec as a contract research organization to conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods for NB4168. Work will be executed in collaboration with NAD Pharmaceuticals Corp., Niagen Bioscience’s wholly owned subsidiary focused on therapies for accelerated aging and rare genetic diseases. The studies will take place at Evotec’s campus in Verona, Italy, utilizing the company’s INDiGO platform, which integrates active pharmaceutical ingredient development, drug product development, safety assessments, and regulatory services to streamline the path to clinical evaluation.

"Selecting Evotec adds streamlined drug development capabilities and executional scale to the NB4168 program," said Ozan Pamir, Chief Financial Officer of Niagen Bioscience. "This collaboration is an important step in building the pharmacological and bioanalytical evidence required to advance NB4168 toward clinical evaluation in patients with A-T."

NB4168 is designed to deliver significantly increased exposure to nicotinamide riboside (NR) compared to NR chloride, supporting its development as a more bioavailable pharmaceutical candidate. In nonclinical pharmacokinetic studies conducted to date, NB4168 demonstrated substantially higher blood exposure than NR chloride. Existing research on NR in A-T, including independent open-label clinical studies, has reported improvements in neurological measures and related biomarkers, providing a biological rationale for this approach.

Development Milestones and Regulatory Status

Niagen Bioscience has received both FDA Rare Pediatric Disease Designation and European Medicines Agency Orphan Medicinal Product Designation for NB4168 for the treatment of A-T. The company is currently advancing preclinical development activities with plans to submit an IND application to the FDA in anticipation of initiating human clinical studies.

Ataxia Telangiectasia is a rare genetic disease caused by mutations in the ATM gene, affecting roughly 1 in 40,000 people in the U.S. and 1 in 150,000 people in Europe. The condition is characterized by progressive loss of motor coordination, impaired immune function, and an elevated risk of cancer. There are currently no FDA-approved therapies for A-T, and treatment remains largely limited to supportive care.

Strategic Partnership Dynamics

Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry. Dr. Ashiq Khan, Executive Vice President and Chief Commercial Officer of Evotec, stated that the collaboration demonstrates the value of Evotec’s integrated development offering in supporting innovative companies as they advance assets toward the clinic. He noted that NB4168 is a promising program supported by a defined biological rationale and a focused preclinical development plan.

The partnership allows Niagen Bioscience to leverage Evotec’s vertically integrated model, which is designed to accelerate timelines, reduce development risk, and improve cost efficiency. By consolidating ICH-directed activities required for early-phase clinical evaluation—including absorption, distribution, metabolism, excretion, and regulatory services—within a single platform, the companies aim to optimize the transition from preclinical data to first-in-human studies.